In today's Pharmaceutical Executive Daily, the FDA's Oncologic Drugs Advisory Committee votes a favorable benefit-risk ...
FDA cleared the first agent with an NMDA/sigma-1–based mechanism specifically for agitation in Alzheimer’s disease dementia, ...
ODAC voted 7–1 (one abstention) that capivasertib plus abiraterone and ADT shows a favorable benefit–risk profile for ...
In a conversation with Pharmaceutical Executive, Jeff Golfman, founder and president of Send 123, discusses how and why ...
Aradigm CEO Will Shrank discusses the significant challenge payers face in predicting and managing the costs of cell and gene ...
Synchronizing sales and marketing around a unified, customer-centric approach is essential for pharmaceutical companies ...
Building manufacturer partnerships depends on trust, data-driven insights, and integrated teams spanning market access, ...
In the final part of his interview, Jeff Golfman discusses how data-driven supply chain mapping and collaborative procurement ...
Aradigm CEO Will Shrank discusses the significant challenge payers face in predicting and managing the costs of cell and gene therapies due to their volatility and unpredictability. Will Shrank, CEO ...
While advances in cell & gene therapy continue to show promise for creating new treatments, this sector of the industry still ...
Shareholder approval positions Garijo to steer strategy toward operational rigor, portfolio discipline, and more consistent ...
GLP-1 agonists have become the dominant spend catalyst, with class spending ~$132B and growth contribution approaching ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results